US Stock Movement: Arcadia plunges on September 24 as main endpoint not met and phase III risks emerge

Arcadia September 24 Large Drop Interpretation

Keywords: Primary endpoint not met, phase III risks

1. On September 24, 2026, Arcadia announced the results of the phase II trial of pimavanserin in treating Alzheimer's disease psychosis. The 60mg dose did not reach statistical significance on the primary endpoint SAPS-H+D (p=0.0603), weakening certainty about efficacy and increasing subsequent development risk.

2. On September 24, 2026, the 30mg dose in the trial showed limited improvement compared to placebo. When advancing to phase III, the company removed this dose and retained only the 60mg dose; although the key secondary endpoint was nominally significant, further trials are still needed for confirmation.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only, not investment advice.)